Pathogenesis, diagnostics and treatment of Helicobacter pylori infection;Pathogenese, Diagnostik und Therapie der Helicobacter-pylori-Infektion

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 48, Issue 6, 2005, Pages 669-678

  Kist, Manfred ^a   Glocker, E ^a   Suerbaum, Sebastian ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Diagnostics; Helicobacter pylori; Pathogenesis; Treatment

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL PRACTICE; HELICOBACTER; HELICOBACTER INFECTION; HUMAN; PRACTICE GUIDELINE;

ANTI-BACTERIAL AGENTS; HELICOBACTER; HELICOBACTER INFECTIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 22144445268     PISSN: 14369990     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00103-005-1065-y     Document Type: Article

References (63)

1. Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347:1175-1186
2. Falush D, Wirth T, Linz B et al. (2003) Traces of human migrations in Helicobacter pylori populations. Science 299:1582-1585
3. Levi F, Lucchi ni F, Gonzalez JR et al. (2004) Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 15:338-345
4. Alm RA, Ling LS, Moir DT et al. (1999) Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397:176-180
5. Tomb JF, White O, Kerlavage AR et al. (1997) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388:539-547
6. Josenhans C, Suerbaum S (2001) Motility and chemotaxis. In: Achtmann M, Suerbaum S (eds) Helicobacter pylori: Molecular and cellular biology. Molecular and Cellular Biology, Wymondham Scientific Press, pp 171-184
7. Schreiber S, Konradt M, Groll C et al. (2004) The spatial orientation of Helicobacter pylori in the gastric mucus. Proc Natl Acad Sci USA 101:5024-5029
8. Ilver D, Arnqvist A, Ogren J et al. (1998) Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 279:373-377
9. Mahdavi J, Sonden B, Hurtig M et al. (2002) Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 297:573-578
10. Suerbaum S, Maynard Smith J, Bapumia K et al. (1998) Free recombination within Helicobacter pylori. Proc Natl Acad Sci USA 95:12619-12624
11. Falush D, Kraft C, Taylor NS et al. (2001) Recombination and mutation during long-term gastric colonization by Helicobacter pylori: Estimates of clock rates, recombination size, and minimal age. Proc Natl Acad Sci USA 98:15056-15061
12. Blaser MJ, Atherton JC (2004) Helicobacter pylori persistence: Biology and disease. J Clin Invest 113:321-333
13. Censini S, Lange C, Xiang Z et al. (1996) cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 93:14648-14653
14. Odenbreit S, Puls J, Sedlmaier B et al. (2000) Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287:1497-1500
15. Selbach M, Moese S, Hurwitz R et al. (2003) The Helicobacter pylori CagA protein induces cortactin dephosphorylation and actin rearrangement by c-Src inactivation. EMBO J 22:515-528
16. Lee SK, Stack A, Katzowitsch E et al. (2003) Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 5:1345-1356
17. Viala J, Chaput C, Boneca IG et al. (2004) Nod1 responds to peptidogly can delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 5:1166-1174
18. Mohammadi M, Nedrud J, Redline R et al. (1997) Murine CD4 T-cell response to Helicobacter infection: TH1 cells enhance gastritis and TH2 cells reduce bacterial load. Gastroenterology 113:1848-1857
19. Machado JC, Figueiredo C, Canedo P et al. (2003) A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 125:364-371
20. Kist M, Strobel S, Kirchner T, Dammann HG (1999) Impact of ELISA and immunoblot as diagnostic tools one year after eradication of Helicobacter pylori in a multicentre treatment study. FEMS Immunol Med Microbiol 24:239-242
21. Anonymus (1995) Leitlinie der Deutschen Gesellschaft für Ver dauungs- und Stoffwechselkrank heiten. Diagnostik und Therapie der Helicobacter-pylori-Infektion. Z Ga stroente rol 34:392-401
22. Kist M, Glocker E (2003) Helicobacter-pylori-In fektionen: ResiNet - eine bundesweite Sentinelstudie zur Resistenzentwicklung. Epidemiol Bull 47:389-391
23. Rathbone BJ, Wyatt JI, Worsley BW et al. (1986) Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia. Gut 27:642-647
24. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ (1988) Campylobacter pylori antibodies in humans. Ann Intern Med 109:11-17
25. Apel I, Jacobs E, Kist M, Bredt W (1988) Antibody response of patients against a 120 kDa surface protein of Campylobacter pylori. Zentralbl Bakteriol Mikrobiol Hyg [A] 268:271-276
26. Kimmel B, Bosserhoff A, Frank R et al. (2000) Identification of immunodominant antigens from Helicobacter pylori and evaluation of their reactivities with sera from patients with different gastroduodenal pathologies. Infect Immun 68:915-920
27. Laheij RJ, Straatman H, Jansen JB, Verbeek AL (1998) Evaluation of commercially available Helicobacter pylori serology kits: A review. J Clin Microbiol 36:2803-2809
28. Cutler AF, Havstad S, Ma CK et al. (1995) Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 109:136-141
29. Jaskowski TD, Martins TB, Hill HR, Litwin CM (1997) Immunoglobulin A antibodies to Helicobacter pylori. J Clin Microbiol 35:2999-3000
30. Fabris P, Bozzola L, Benedetti P et al. (1997) H. pylori infection in HIV-positive patients. A serohistological study. Dig Dis Sci 42:289-292
31. Graham DY, Opekun AR, Hammoud F et al. (2003) Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 98:1005-1009
32. Manes G, Balzano A, Iaquinto G et al. (2001) Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy. Aliment Pharmacol Ther 15:73-79
33. Vaira D, Vakil N (2001) Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 48:287-289
34. Machado RS, Patricio FR, Kawakami E (2004) 13C-urea breath test to diagnose Helicobacter pylori infection in children aged up to 6 years. Helicobacter 9:39-45
35. Carvalho Costa CL, Rocha GA, Rocha AM et al. (2003) Evaluation of [13C] urea breath test and Helicobacter pylori stool antigen test for diagnosis of H. pylori infection in children from a developing country. J Clin Microbiol 41:3334-3335
36. Peitz U, Leodolter A, Wex T et al. (2004) Diagnostics of Helicobacter pylori infection in patients with pepticulcer bleeding. Z Gastroenterol 42:141-146
37. Udd M, Miettinen P, Palmu A, Julkunen R (2003) Effect of short-term treatment with regular or high doses of omeprazole on the detection of Helicobacter pylori in bleeding peptic ulcer patients. Scand J Gastroenterol 38:588-593
38. Gisbert JP, Pajares JM (2004) Stool antigen test for the diagnosis of Helicobacter pylori infection: A systematic review. Helicobacter 9:347-368
39. Koletzko S, Konstantopoulos N, Bosman D et al. (2003) Evaluation of a novel monoclonal enzyme immunoassay for detection of Helicobacter pylori antigen in stool from children. Gut 52:804-806
40. Dunn BE, Cohen H, Blaser MJ (1997) Helicobacter pylori. Clin Microbiol Rev 10:720-741
41. Monteiro L, de Mascarel A, Sarrasqueta AM et al. (2001) Diagnosis of Helicobacter pylori infection: Noninvasive methods compared to invasive methods and evaluation of two new tests. Am J Gastroenterol 96:353-358
42. He Q, Wang JP, Osa to M, Lachman LB (2002) Realtime quantitative PCR for detection of Helicobacter pylori. J Clin Microbiol 40:3720-3728
43. Kobayashi D, Eishi Y, Ohkusa T et al. (2002) Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. J Med Microbiol 51:305-311
44. Matsumura M, Hikiba Y, Ogura K et al. (2001) Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J Clin Microbiol 39:691-695
45. Oleastro M, Menard A, Santos A et al. (2003) Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 41:397-402
46. Lascols C, Lamarque D, Costa JM et al. (2003) Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H. pylori isolates from gastric biopsy specimens by real-time PCR. J Clin Microbiol 41:4573-4577
47. Glocker E, Kist M (2004) Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol 42:2241-2246
48. Malfertheiner P, Megraud F, O'Morain C et al. (2002) Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180
49. Moayye di P, Soo S, Deeks J et al. (2000) Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 321:659-664
50. Murakami K, Fujioka T, Okimoto T et al. (2002) Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 19:67-70
51. Bayerdorffer E, Lind T, Dite P et al. (1999) Omeprazole, amoxycillin and metronidazole for the cure of Heliobacter pylori infection. Eur J Gastroenterol Hepatol 11 [Suppl 2]:S19-22
52. McLoughlin R, Racz I, Buckley M et al. (2004) Therapy of Helicobacter pylori. Helicobacter 9 [Suppl 1]:42-48
53. Zullo A, Vaira D, Vakil N et al. (2003) High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 17:719-726
54. Peitz U, Hackelsberger A, Malfertheiner P (1999) A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard the rapy. Drugs 57:905-920
55. Gisbert JP, Calvet X, Bujanda L et al. (2003) "Rescue" therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 8:90-94
56. Zullo A, Hassan C, De F et al. (2003) A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 35:232-236
57. Watanabe Y, Aoyama N, Shirasaka D et al. (2003) Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 35:711-715
58. Wong WM, Gu Q, Lam SK et al. (2003) Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treat ment for Helicobacter pylori infection. Aliment Pharmacol Ther 17:553-560
59. Ojetti V, Migneco A, Zocco MA et al. (2004) Beta-lacta mase inhibitor enhances Helicobacter pylori eradication rate. J Intern Med 255:125-129
60. Malfertheiner P, Peitz U, Wolle K, Treiber G (2004) Helicobacter pylori infection - update for the clinician 2004. Dtsch Med Wochenschr 20(129):1821-1826
61. Gisbert JP, Hermida C, Pajares JM (2001) Are twelve days of omeprazole, amoxicillin and clarithromycin better than six days for treating H. pylori infection in peptic ulcer and in non-ulcer dyspepsia? Hepatogastroenterology 48:1383-1388
62. Lamouliatte H, Megraud F, Delchier JC et al. (2003) Second-line treatment for failure to eradicate Helicobacter pylori: A randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 18:791-797
63. Bazzoli F, Pozzato P, Rokkas T (2002) Helicobacter pylori: The challenge in therapy. Helicobacter 7 [Suppl 1]:43-49